Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [5292]

FDA approves niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer

FDA approves niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant...

Inhibition of prmt5 by repurposing market drugs - a fresh therapeutic pathway for cancer treatment

Inhibition of prmt5 by repurposing market drugs - a fresh therapeutic pathway for cancer treatment

Bioengineered tool unmasks cancer cells

Bioengineered tool unmasks cancer cells

$FDA grants accelerated approval to talquetamab-tgvs for relapsed or refractory multiple myeloma$

FDA grants accelerated approval to talquetamab-tgvs for relapsed or refractory multiple myeloma

CDK9 Inhibitors: A promising combination partner in treating haematological malignancies

CDK9 Inhibitors: A promising combination partner in treating haematological malignancies

FDA approves pralsetinib for non-small cell lung cancer with RET gene fusions

FDA approves pralsetinib for non-small cell lung cancer with RET gene fusions

New machine-learning method may aid personalised cancer therapy

New machine-learning method may aid personalised cancer therapy

A select group: study may bring improved therapy to preselected lung cancer patients

A select group: study may bring improved therapy to preselected lung cancer patients

DNA breaking process revealed

DNA breaking process revealed

RAGE as a driver of cell plasticity in an aggressive subtype of triple-negative breast cancer

RAGE as a driver of cell plasticity in an aggressive subtype of triple-negative breast cancer

More from ecancer